MedPath

Alfuzosin Hydrochloride

These highlights do not include all the information needed to use alfuzosin hydrochloride safely and effectively. See full prescribing information for alfuzosin hydrochloride. Alfuzosin hydrochloride extended-release tablets, USP for Oral UseInitial U.S. Approval: 2003

Approved
Approval ID

3cc028d5-309f-4ce3-a2d7-5804ab57677d

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Oct 1, 2020

Manufacturers
FDA

Cipla USA Inc.

DUNS: 078719707

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Alfuzosin Hydrochloride

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code69097-844
Application NumberANDA090284
Product Classification
M
Marketing Category
C73584
G
Generic Name
Alfuzosin Hydrochloride
Product Specifications
Route of AdministrationORAL
Effective DateMay 28, 2020
FDA Product Classification

INGREDIENTS (6)

ALFUZOSIN HYDROCHLORIDEActive
Quantity: 10 mg in 1 1
Code: 75046A1XTN
Classification: ACTIB
MICROCRYSTALLINE CELLULOSEInactive
Code: OP1R32D61U
Classification: IACT
HYPROMELLOSE, UNSPECIFIEDInactive
Code: 3NXW29V3WO
Classification: IACT
GUAR GUMInactive
Code: E89I1637KE
Classification: IACT
SILICON DIOXIDEInactive
Code: ETJ7Z6XBU4
Classification: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Alfuzosin Hydrochloride - FDA Drug Approval Details